 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | bavisant (JNJ-31001074) / J&J, BenevolentAI, Wakix (pitolisant) / Ferrer International, Paragon Biosci
Journal: Histamine receptors, agonists, and antagonists in health and disease. (Pubmed Central) - Jul 30, 2021
Pitolisant, a H3 receptor antagonist, is used to treat narcolepsy and hypersomnia...H2 receptor antagonists have shown efficacy in treatment of schizophrenia, but they are not in widespread clinical use. H4 receptor ligands may in the future be tested for neuroimmunological disorders and potentially neurodegenerative disorders in which inflammation plays a role, but clinical tests have not yet been initiated.
- | bavisant (JNJ-31001074) / J&J, BenevolentAI
Trial completion, Trial completion date, Trial primary completion date: CASPAR: BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness (clinicaltrials.gov) - Jul 10, 2019
P2b, N=248, Completed, Sponsor: BenevolentAI Bio
H4 receptor ligands may in the future be tested for neuroimmunological disorders and potentially neurodegenerative disorders in which inflammation plays a role, but clinical tests have not yet been initiated. Recruiting --> Completed | Trial completion date: Aug 2018 --> May 2019 | Trial primary completion date: Jun 2018 --> May 2019
- | bavisant (JNJ-31001074) / J&J, BenevolentAI
Enrollment open: CASPAR: BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness (clinicaltrials.gov) - Dec 4, 2017
P2b, N=230, Recruiting, Sponsor: BenevolentAI Bio
Recruiting --> Completed | Trial completion date: Aug 2018 --> May 2019 | Trial primary completion date: Jun 2018 --> May 2019 Not yet recruiting --> Recruiting
- | bavisant (JNJ-31001074) / J&J, BenevolentAI
New P2b trial: CASPAR: BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness (clinicaltrials.gov) - Jun 20, 2017
P2b, N=230, Not yet recruiting, Sponsor: BenevolentAI Bio
- bavisant (JNJ-31001074) / J&J, BenevolentAI
Enrollment change: A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women (clinicaltrials.gov) - Sep 20, 2016
P1, N=0, Withdrawn, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting N=32 --> 0
- bavisant (JNJ-31001074) / J&J, BenevolentAI
Trial withdrawal: Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults (clinicaltrials.gov) - Feb 5, 2012
P2, N=0, Withdrawn, Sponsor: Janssen Research & Development, LLC
N=32 --> 0 Not yet recruiting --> Withdrawn